IBERE PHARMACEUTICALS

Ibere Pharmaceuticals Acquisition Corp (Nasdaq: IBER) is a blank-check company formed to pursue a business combination in the pharmaceutical and life sciences sector. The company filed a Form 10-Q with the SEC on May 16, 2022, reflecting its status as an active SPAC searching for a target in the healthcare and biopharma space. Ibere completed its initial public offering in 2021, positioning itself within one of the most active SPAC sectors of that era as investor interest in life sciences transactions remained elevated. The SPAC structure targeted pharmaceutical development and commercialization opportunities. Visit SpacDesk and sign up for full data, filings, and deal-status tracking on IBER and hundreds of other active and historical SPACs.